For the disease- and immunity-related pathways, “Bladder cancer”, “Non-alcoholic fatty liver disease”, “CAMP resistance”, and “Platinum drug resistance” were identified. This evidence concerns the gene CAMP and metabolic dysfunction-associated steatotic liver disease.